Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types

Lancet Oncol. 2017 May;18(5):556-557. doi: 10.1016/S1470-2045(17)30227-9. Epub 2017 Mar 31.

Authors

Athanasios Kotsakis¹, Vassilis Georgoulias²

Affiliations

¹ Hellenic Oncology Research Group (HORG), Lombardou, Athens, Greece.
² University of Crete, School of Medicine, Voutes, 711 10 Heraklion, Crete. Electronic address: georgsec@med.uoc.gr.

PMID: 28373006
DOI: 10.1016/S1470-2045(17)30227-9

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal*
Antibodies, Monoclonal, Humanized
B7-H1 Antigen*
Humans
Neoplasms

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
B7-H1 Antigen
avelumab